# Safety, Tolerability and Renal Effects of APX-115 in Subjects With Type 2 Diabetes and Nephropathy

> **NCT04534439** · PHASE2 · COMPLETED · sponsor: **Aptabio Therapeutics, Inc.** · enrollment: 140 (actual)

## Conditions studied

- Diabetic Nephropathies
- Diabetes Mellitus, Type 2
- Nephropathy, Diabetic

## Interventions

- **DRUG:** APX-115
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04534439
- **Lead sponsor:** Aptabio Therapeutics, Inc.
- **Sponsor class:** INDIV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-24
- **Primary completion:** 2021-07-26
- **Final completion:** 2021-08-23
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2021-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04534439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04534439, "Safety, Tolerability and Renal Effects of APX-115 in Subjects With Type 2 Diabetes and Nephropathy". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT04534439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*